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Using immunobiochemical approaches we previously studied the conformation and surface exposure of different immuno-
dominant regions within the oligomeric, virion-associated form of the gp120 envelope glycoprotein of the human immunodefi-
ciency virus type 1 (HIV-1) (L. Stamatatos and C. Cheng-Mayer (1995) J. Virol. 69, 6191–6198). These studies allowed us
to determine to what extent epitopes within these immunodominant regions of the oligomeric gp120 are occluded or
accessible to antibody binding on the virion surface of two primary-like (HIV-1SF162 and HIV-1SF128A) and one T-cell-line-
adapted (HIV-1SF2) isolates. Here, we investigate whether binding of anti-gp120 monoclonal antibodies (MAbs) to exposed
epitopes of the immunodominant regions of oligomeric gp120 results in neutralization of HIV-1 infection and whether certain
exposed sites are better targets for neutralization than others. We also test whether proposed mechanisms for antibody-
mediated neutralization of T-cell-line-adapted HIV-1 isolates, e.g., antibody-mediated gp120-virion dissociation, are applicable
to primary-like HIV-1 isolates. We assess the neutralization potential of anti-V2 loop, anti-V3 loop, and anti-CD4 binding site
MAbs using human primary macrophages or peripheral blood mononuclear cells (PBMC) as target cells and HIV-1SF162 and
HIV-1SF128A as infecting isolates. Our data indicate that: (i) not every exposed epitope of the immunodominant regions of
gp120 oligomers on the virion surface is a target for neutralization; (ii) during virus–cell fusion specific exposure of previously
occluded V3 loop epitopes within gp120 oligomers occurs, which may become targets for neutralization; (iii) antibody-
mediated gp120-virion dissociation does not appear to be a major mechanism of neutralization for the primary-like HIV-1
isolates tested here; and (iv) infection of macrophages is more sensitive to neutralization by anti-gp120 monoclonal antibodies
than PBMC. We also report that binding of one of the two anti-CD4 binding site MAbs tested mediated enhancement of
macrophage cell infection in a concentration-dependent fashion, while binding of the other anti-CD4 binding site MAb
resulted in efficient neutralization of infection of both macrophages and PBMC. q 1997 Academic Press
INTRODUCTION gp120 molecules (Stamatatos and Cheng-Mayer, 1995).
These studies revealed that in the absence of virion-CD4
In an effort to understand how the structure of the
binding, virion-associated gp120 molecules of primary-
envelope glycoprotein of the human immunodeficiency
like macrophage-tropic HIV-1 isolates are oligomerized
virus type 1 (HIV-1) regulates certain biological proper-
in a way that certain V3 loop epitopes are occludedties of this virus, such as its cellular tropism, cytopathol-
and inaccessible to MAb binding, in accordance withogy, and neutralization sensitivity to antibodies and re-
reports from other investigators (Bou-Habib et al., 1994;combinant soluble receptor (sCD4), we began probing
Sullivan et al., 1995). This observation contrasts with thatthe conformation of the gp120 envelope subunit of iso-
made using laboratory-adapted, T-cell-line-tropic viruseslates displaying distinct phenotypes in vitro using immu-
whose V3 loop appears exposed and accessible to MAbnochemical approaches (Harrowe, 1995; Koito et al.,
binding on virions and infected T-cell-lines (Bou-Habib1995; Stamatatos and Cheng-Mayer, 1993, 1995; Stama-
et al., 1994; Sattentau and Moore, 1995; Stamatatos andtatos et al., 1994). We determined the relative binding
Cheng-Mayer, 1995; Sullivan et al., 1995). Contrary to theaffinity (based on half maximal antibody–virion binding
occluded nature of their V3 loop, the V2 loop and CD4-values) and maximal extent of binding (antibody bound
binding site of macrophage-tropic primary-like isolatesto virions at saturation) of monoclonal antibodies (MAbs)
are accessible to antibody binding (Stamatatos andto the V2 loop (MAbs G3.4 and G3.136), the V3 loop
Cheng-Mayer, 1995).(MAbs 257D, 268D, and 391-95D), and the CD4-binding
Here we attempted to correlate the virion-binding prop-site (MAbs 654-30D and 559-64D) of virion-associated
erties of the MAbs mentioned above with their neutraliza-
tion potential, in both PBMC and macrophages, against1 To whom correspondence and reprint requests should be addressed
two primary-like macrophage-tropic HIV-1 isolates, HIV-at Aaron Diamond AIDS Research Center, 455 First Ave., 7th floor, New
York, NY 10016. Fax: (212) 725-1126. E-mail: leonidas@adarc.org. 1SF162 and HIV-1SF128A . Our goal was to begin to under-
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stand the mechanisms whereby primary HIV-1 isolates, the NIH AIDS research and Reference Reagent Program.
The anti-gp120 and anti-gp41 sheep polyclonal antibod-which may be relatively resistant to antibody and sCD4
neutralization (Cheng-Mayer et al., 1988; Moore et al., ies, D6205 and D6204, respectively, were purchased
from International Enzymes, Inc. (Fallbrook, CA).1992, 1995; Moore and Ho, 1995; Sawyer et al., 1994;
Sullivan et al., 1995) can in fact be neutralized by certain
MAbs. Quantitation of monoclonal antibody binding to intact
Several studies have previously examined the mecha- virions, gp120 monomers, and antibody-mediated
nisms of antibody- and sCD4-mediated neutralization for dissociation of gp120 molecules from the virion
T-cell-line-adapted HIV-1 isolates. These studies have surface
suggested correlations between the neutralization poten-
tial of MAbs (or sCD4) with: (i) their association rate Quantitation of MAbs bound to intact virions and soluble
gp120 molecules was performed by an assay we describedconstant (Sattentau and Moore, 1995), (ii) their dissocia-
tion rate constant (VanCott et al., 1994), (iii) their ability to previously (Stamatatos and Cheng-Mayer, 1995). Briefly, ali-
quots of sucrose purified virions are divided into two equalpromote gp120-virion-dissociation (Poignard et al., 1995),
and (iv) the degree of exposure of the epitopes they fractions. One fraction is first treated with detergent (1%
NP-40) to generate soluble gp120 molecules and then incu-recognize on the oligomeric form of the envelope (Bou-
Habib et al., 1994; Sattentau and Moore, 1995; Sullivan bated with MAbs (0.01 to 20 mg/ml) for 3 hr at 377. Following
that period, the gp120/MAb mixtures are added to 96-wellet al., 1995). In this study we tested to what degree the
proposed neutralization mechanisms for T-cell-line- plates, whose wells are precoated with sheep polyclonal
antibodies (D6205) against the carboxyl terminal of gp120.adapted isolates might also apply to primary-like HIV-
1 isolates, because we believe that elucidation of the MAbs associated with D6205 captured gp120 molecules
are detected with the use of the appropriate alkaline phos-mechanisms by which antibodies neutralize primary HIV-
1 isolates is central to the development of effective anti- phatase-coupled anti-MAb antibody (Zymed Laboratories
Inc., South San Francisco, CA). Thereafter, with the use ofHIV-1 vaccine strategies.
an enzyme-linked immunosorbent assay (ELISA), the rela-
tive amounts of MAbs bound to gp120 are quantitated byMATERIALS AND METHODS
determining the optical density at 490 nm ([OD490]) withViruses and antibodies
the appropriate secondary antibodies coupled to alkaline
phosphatase (Stamatatos and Cheng-Mayer, 1995; Stama-Molecular clones of HIV-1SF162 and HIV-1SF128A isolates
were used. The biological properties of these isolates tatos et al., 1994). The other fraction (intact virions) is directly
incubated with MAbs as above. The relative quantities ofhave been previously reported (Cheng-Mayer et al., 1990;
Liu et al., 1990). Briefly, HIV-1SF162 and HIV-1SF128A do not virion-associated MAbs are determined following pelleting
of the virions by centrifugation (15,000 g for 90 min at 47).infect established T-cell-lines and are relatively resistant
to serum and sCD4 neutralization (Cheng-Mayer et al., During this step the non-virion-associated MAbs (vast ma-
jority of the total MAb added to the virions) remains in1988; Stamatatos et al., 1994). The viruses were gener-
ated by transfection of the viral DNA into RD-4 cells or solution, while the virion-bound MAbs are present in the
virion pellet. The pelleted virions are then lysed with 1%293-T cells and cocultivation with PHA-stimulated (3 mg/
ml for 3 days) human peripheral blood mononuclear cells NP-40 and the generated gp120-MAb soluble complexes
are added to D6205-coated 96-well plates as described(PBMC) as previously reported (Cheng-Mayer et al.,
1990). Human primary macrophages were prepared by above.
Upon MAb-virion binding, some gp120–MAb com-the plastic adherence method as previously described
(Cheng-Mayer et al., 1989) with the only modification be- plexes may dissociate from the virion surface. These
soluble complexes are present in the supernatant of theing that the wells were coated with polylysine (Sigma,
St. Louis, MS) prior to addition of monocyte cells. The pelleted virions and are separately captured on 96-well
plates coated with D6205 as described above. Thereforeisolation and characterization of the human anti-V3
MAbs, 391-95D, 257D, and 268D, human anti-CD4 bind- the relative quantities of gp120 molecules that become
dissociated from the virion surface following their associ-ing site MAbs, 654/30D and IgG1b12, were previously
described (Burton et al., 1994; Gorny et al., 1993; Laal et ation with MAbs can be determined with the use of the
above ELISA assay (Stamatatos and Cheng-Mayer,al., 1994). The murine anti-V2 MAbs, G3.4 and G3.136,
were characterized previously (Fung et al., 1992) and 1995). For each MAb concentration added to the virions
we determined both the amount of MAb present in thewere generously provided by Taxon Biosystems Inc.
(Houston, TX). The human anti-CD4 binding site MAb viral pellet and that found complexed with gp120 in the
supernatant. Spontaneous release of gp120 moleculesIgG1b12 was provided by Dennis Burton (The Scripps
Research Institute, La Jolla, CA). The human anti-gp41 from the virion surface was determined by incubating the
virions in the absence of MAb under the above describedMAb 2F5 was provided by Alexandra Trkola (ADARC,
New York, NY), and the 50-69 MAb was obtained from conditions. The amounts of gp120 present in the super-
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natant of the viral pellet were determined as above and medium). Triplicate wells of 96-well plates were used for
each MAb concentration. In negative control wells, virusthe recorded OD490 nm values were substracted from
those obtained when virions were incubated with MAb. was incubated with cells in the absence of MAb. Seven
days later, the p24 antigen concentration of each well
was determined. The IC90 and IC50 values are determinedQuantitation of exposure of gp41 epitopes on the
as above.virion surface mediated by binding of anti-gp120
MAbs to intact virions
RESULTSSucrose-purified virions are incubated with increasing
concentrations (0, 0.01, 0.1, 0.5, 1, and 10 mg/ml) of hu- Neutralization of PBMC and macrophage-infection by
man anti-CD4-binding site MAbs (654-30D or IgG1b12) monoclonal antibodies to the third hypervariable
and a fixed concentration (1 mg/ml) of human anti-gp41 region of gp120
MAbs (50-69 or 2F5). The binding of anti-gp41 MAbs to
We previously reported on the binding kinetics of threethe virion surface, as a function of the concentration of
human anti-V3 loop MAbs (257D, 268D, and 391-95D) tothe anti-gp120 MAb concentration added, is determined
virion-associated and soluble gp120 molecules from HIV-as described above by capturing gp41–MAb complexes
1SF162 and HIV-1SF128A isolates (Stamatatos and Cheng-(following virion disruption by 1% NP-40) on wells coated
Mayer, 1995). These data are summarized in Table 1.with polyclonal anti-gp41 antibodies (D6204).
Briefly, MAb 391-95D binds more extensively than MAb
257D on the surface of HIV-1SF162 and HIV-1SF128A virions,Neutralization of infection
while MAb 268D shows very poor binding reactivity
(a) Macrophages. Viruses (100 TCID50 units in 100 ml against these two isolates. A preferential exposure of the
of cell medium) are preincubated with an equal volume epitope recognized by MAb 391-95D over those recog-
of serially diluted MAbs (0.01 to 20 mg/ml) for 1 hr at 377. nized by MAbs 257D and 268D is observed upon virion-
The virus–MAb mixture is then incubated with human sCD4 binding. Presently, we tested the neutralization po-
primary macrophage cells for 3 hr at 377. The viral inocu- tential of these MAbs against HIV-1SF162 and HIV-1SF128A
lum is subsequently removed and the cells are washed in PBMC and primary macrophages as cell targets. As
several times with Hank’s buffer. Infection is determined summarized in Table 2, MAb 391-95D is more potent in
by quantitating the p24 antigen concentration in the cell neutralizing the infection of primary macrophage cells
medium 7 (for HIV-1SF162) and 10 (for HIV-1SF128A) days and PBMC by HIV-1SF162 and HIV-1SF128A than MAb 257D.
later. The percentage neutralization of infection for each MAb 268D had no effect on viral infectivity. The neutral-
MAb concentration tested is determined by comparing ization potentials of MAbs 391-95D and 257D (based on
the p24 concentration of the experimental control (i.e., the IC90 and IC50 values) against both isolates are
macrophages infected by HIV-1 in the absence of MAbs) stronger when the target cells are primary macrophages
as follows: than PBMC (Table 2).
Percentage neutralization
Neutralization of PBMC and macrophage-infection by
 [(control) 0 (experimental)/(control)] 1 100, monoclonal antibodies to the second hypervariable
region of gp120
where control is p24 concentration in wells where virus is
incubated with macrophages in the absence of MAb and We previously reported on the binding of the murine
anti-V2 loop MAbs G3.4 and G3.136 to soluble and virion-experimental is p24 concentration in wells where virus is
incubated with macrophages in the presence of MAb. associated gp120 molecules of HIV-1SF162 and HIV-1SF128A
isolates (Stamatatos and Cheng-Mayer, 1995) and addi-A curve is then generated by plotting the percentage
neutralization versus antibody concentration, and the an- tional confirmatory data are shown in Fig. 1 and Table 1.
Binding of MAb G3.136 to either isolate does not mediatetibody concentrations that reduce the infectivity by 90
and 50% as compared to control (IC90 and IC50, respec- gp120-virion dissociation (data not shown). In contrast,
binding of MAb G3.4 to HIV-1SF162 , but not HIV-1SF128A ,tively) are presented in Table 2.
MAb-mediated enhancement of infection is indicated mediates substantial release of gp120 molecules from
the virion surface in the form of gp120-G3.4 complexeswhen (experimental)  (control). We define MAb-medi-
ated enhancement of HIV-1 (for a given MAb concentra- (Fig. 1). At 10 mg/ml MAb G3.4, between 40 and 50%
of the virion-associated gp120 molecules that becometion) as at least a twofold increase in infection in the
presence of MAb, as compared to control infections. associated with MAb G3.4 are released from the virion
surface of HIV-1SF162 as gp120/MAb G3.4 complexes dur-(b) Peripheral blood mononuclear cells. One hundred
TCID50 units in 50 ml were incubated with serial dilutions ing a 3-hr incubation period. However, irrespective of
their binding characteristics (maximal extent of binding,of an equal volume of MAb for 1 hr at 377. The mixture
was then added to PBMC (4 1 105 in 100 ml of cell relative binding affinities, and gp120-virion dissociation
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TABLE 1
Binding of MAbs to Intact HIV-1SF162 and HIV-1SF128A Virions
sCD4 effect b
Maximal Half-maximal
MAb gp120 region bindinga (a) (b) bindingc
391-95D V3 loop 0.3 (0.1) 0.05 1.0 0.1 (0.025) 0.15 (0.025)
257D V3 loop 0.15 (0.05) ND 0.25 0.15 (0.05) 0.15 (0.05)
268D V3 loop ND ND ND ND ND
G3.4 V2 loop 1.5 (0.35) 0.1 0.1 1 (0.2) 1.5 (0.2)
G3.136 V2 loop 0.5 (0.18) NT NT 1.7 (0.3) 4.9 (0.25)
654-30D CD4 binding site 0.9 (0.2) NT NT 0.3 (0.1) 0.4 (0.15)
IgG1b12 CD4 binding site 0.4 (0.1) NT NT 0.1 (0.025) 0.3 (0.1)
Note. NT, not tested; ND, not determined with accuracy because of poor MAb-virion reactivity.
a The maximal values (OD490nm) of antibody binding to intact HIV-1SF162 virions shown here are the average and standard deviation (in parenthesis)
from at least three independent experiments and were obtained at saturation of binding (10 mg/ml of MAb added to virions).
b Column (a) indicates the extent of MAb-virion binding (OD490nm) when 0.1 mg/ml MAb were added to HIV-1SF162 virions in the absence of sCD4
and column (b) in the presence of 100 nM sCD4. Similar results were obtained with HIV-1SF128A (Stamatatos and Cheng-Mayer, 1995).
c The half-maximal MAb-virion binding values (mg/ml) were obtained as described elsewhere (Stamatatos and Cheng-Mayer, 1995). The left
column was obtained with HIV-1SF162 and the right column was obtained with HIV-1SF128A . The values represent the average and standard deviation
(in parenthesis) from at least three independent experiments.
capabilities), both G3.4 and G3.136 MAbs failed to neu- Neutralization and enhancement of infection mediated
by monoclonal antibodies to the CD4-binding site oftralize infection of PBMC and primary macrophages by
these two isolates to any significant extent (IC90 was not gp120
attained even at 20 mg/ml concentration) (Table 2).
The human MAbs IgG1b12 and 654-30D bind to the
TABLE 2 CD4-binding domain of gp120 and efficiently neutralize
several laboratory adapted isolates (Burton et al., 1994;IC90 and IC50 Neutralization Values for the MAbs Testeda
Laal et al., 1994; L. Stamatatos et al., unpublished obser-
IC90 IC50 vations). In addition, MAb IgG1b12 was shown to be
potent in neutralizing many primary isolates (Burton et
PBMC Mf PBMC Mf
al., 1994). We previously reported on the binding of MAb
654-30D to HIV-1SF162 and HIV-1SF128A (Stamatatos andHIV-1SF162
Cheng-Mayer, 1995). Here we show that although the
Anti-V3 MAbs
maximal extent of binding of MAb 654-30D to the virion391-95D 20 5 5 2.25
surface is higher than that of MAb IgG1b12 (Fig. 2 and257D — b — 10 15
268D — — — — Table 1), the latter MAb binds to the surface of HIV-1SF162
Anti-V2 MAbs virions with a three time higher relative affinity (based
G3.4 — — — — on half maximal MAb-virion binding values) than the for-
G3.136 — — — —
mer MAb (Table 1 and Fig. 2). The relative binding affinit-Anti-CD4 domain MAb
ies of both MAbs toward HIV-1SF128A are indistinguishableIgGb12 1 0.1 0.1 0.01
(Table 1). Neither MAb mediates significant gp120-virion
dissociation, even at 10 mg/ml (Fig. 2). In neutralizationHIV-1SF128A
assays, MAb IgG1b12 efficiently neutralized both HIV-Anti-V3 MAbs
1SF162 and HIV-1SF128A isolates (Table 2). However, similar391-95D 20 9 15 5
257D — — 10 10 to the anti-V3 neutralizing MAbs (391-95D and 257D),
268D — — — — MAb IgG1b12 is more effective in neutralizing infection
Anti-V2 MAbs of macrophages than PBMC. In contrast MAb 654/30D
G3.4 — — — —
failed to inhibit the infection of PBMC and primary macro-G3.136 — — — —
phages by these two macrophage-tropic viral isolatesAnti-CD4 domain MAb
IgGb12 1 0.1 0.5 0.01 even when present at high concentrations (20 mg/ml). In
fact, when primary macrophages were used as target
a The data indicate the concentration (mg/ml) of MAb required to cells, MAb 654-30D mediated enhancement of infection
reduce infection of peripheral blood mononuclear cells (PBMC) or mac-
by both HIV-1SF162 and HIV-1SF128A in a concentration-de-rophages (Mf) by 90% (IC90) and 50% (IC50). The values are the average
pendent fashion (Fig. 3). The extent of enhancement wasof at least four independent experiments.
b — , ICqo or IC50 not attained at 20 mg/ml. less pronounced when PBMC were used as target cells
AID VY 8443 / 6a2a$$$262 02-18-97 14:13:27 vira AP: Virology
364 STAMATATOS ET AL.
FIG. 1. Binding of anti-V2 loop MAb G3.4 to soluble and virion-associated gp120 molecules of (A) HIV-1SF162 and (B) HIV-1SF128A isolates. Equal
amounts of soluble and virion-associated gp120 molecules were incubated with increasing concentrations (0.1 to 20 mg/ml) of the murine anti-V2
loop MAb G3.4. The relative amounts of MAb G3.4 that became bound (OD 490 nm) to soluble gp120 or the virion surface, as well as the relative
amounts of gp120 molecules that became dissociated from the virion surface following their interaction with MAb G3.4, were determined for each
concentration of MAb G3.4 added. The results shown are representative of at least four independent experiments. The OD490 nm values shown are
corrected for nonspecific MAb binding to the wells (background).
(the maximal enhancement observed was less than two- tested here (Table 2) mediates similar degree of expo-
sure of the gp41 epitopes (Fig. 4). Our data show thatfold as compared to the control infection, data not
shown). neither MAb 654-30D nor MAb IgG1b12 mediated a sig-
nificant increase in the binding of the two anti-gp41 epi-
Gp41 epitope-exposure upon binding of anti-CD4 topes examined (Fig. 4).
binding site MAbs to the surface of intact virions
DISCUSSIONTo examine whether MAb 654-30D mediates enhance-
ment of macrophage infection by inducing exposure of The studies described above were designed and car-
ried out to determine whether the previously proposedgp41 and thus facilitating virus–cell fusion, the binding of
two anti-gp41 MAbs (50-69 and 2F5) to the virion surface mechanisms of antibody-mediated neutralization of T-
cell line-adapted (TCLA) HIV-1 isolates apply to primary-before and during MAb 654-30D-virion association was
determined (Fig. 4). MAb 2F5 neutralizes HIV-1 infection like isolates. We observe that there is no simple pre-
dictive correlation between the virion-binding propertiesby primary HIV-1 isolates (Muster et al., 1993). As a nega-
tive control we tested whether virion-binding of MAb of MAbs and their neutralization potential against primary
HIV-1 isolates. Furthermore, the exposure, or lack of ex-IgG1b12 (which neutralizes infection of the isolates
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FIG. 2. Binding of anti-CD4-binding site MAbs to soluble and virion-associated gp120-molecules of HIV-1SF162 and MAb-mediated dissociation of
gp120 molecules from virions. Equal amounts of soluble and virion-associated gp120 molecules were incubated with increasing concentrations of
two human anti-CD4 binding site MAbs ((A) 654-30D and (B) IgG1b12) as described under Materials and Methods section. The amounts of MAb
bound (OD 490 nm) to soluble gp120, to the virion surface, and those that were released from the virion surface in the form of MAb-gp120 complexes
were determined for each MAb concentration added. The results shown are representative of at least five independent experiments. The OD490 nm
values shown are corrected for nonspecific MAb binding to the wells (background).
posure, of a gp120 epitope on the oligomeric gp120 enve- anti-V2 loop MAbs to the oligomeric envelope of HIV-
1SF162 and HIV-1SF128A (Fig. 1, Table 1) might explain theirlope will not predict whether it will serve as a target for
neutralization by antibodies. For example, the V3 loop poor neutralization potential (Sattentau and Moore,
1995). Other possibilities that cannot be excluded areepitopes recognized by MAbs 391-95D and 257D are
known to be occluded within primary-like virion-associ- that these two MAbs recognize epitopes that are, con-
trary to what was reported for TCLA viruses (Moore etated envelope molecules (Table 1; Stamatatos and
Cheng-Mayer, 1995), yet MAbs 391-95D and 257D do al., 1993), not involved during virus–cell fusion of pri-
mary-like HIV-1 isolates (see below), or less likely, thatneutralize PBMC and macrophage infection by HIV-1SF162
and HIV-1SF128A (Table 2). With respect to the anti-CD4- the epitopes recognized by G3.4 and G3.136 are only
exposed on the surface of defective, noninfectious parti-binding site MAbs tested, MAb IgG1b12 efficiently neu-
tralized infection by HIV-1SF162 and HIV-1SF128A , while MAb cles. Implicit to this last possibility is the requirement
that the binding of some MAbs to noninfectious virion654-30D failed to do so even though the former MAb
bound less extensively to the virion surface than the latter particles differs from that to infectious particles as a re-
sult of different gp120 conformations between these twoMAb at saturation (Fig. 2). In addition, both anti-V2 MAbs
failed to neutralize HIV-1 infection (Table 2) even though populations of virions which are present in any viral prep-
aration. At the present time it is not possible to determinethey both bound more extensively to the virion surface
than the anti-V3 MAbs tested (Table 1; Stamatatos and the percentage of noninfectious virions which arise as a
result of a defective envelope structure. However, previ-Cheng-Mayer, 1995). The poor binding affinities of the
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suggest that this mechanism will not be a predominant
one for primary-like HIV-1 isolates. For example, the bind-
ing of MAb G3.4 to HIV-1SF162 virions resulted in a sub-
stantial amount of gp120-virion dissociation (Fig. 1), yet
this MAb does not neutralize HIV-1SF162 infection (Table
2). Conversely, the anti-V3 loop MAb 391-95D and the
anti-CD4 binding site MAb IgG1b12 neutralize infection
of HIV-1SF162 and HIV-1SF128A effectively (Table 2) without
mediating gp120-virion dissociation (Fig. 2 and data not
shown). Furthermore, the binding of the anti-V2 loop MAb
G3.4, but not MAb G3.136, to the surface of HIV-1SF162
virions resulted in gp120-virion dissociation, while the
binding of MAb G3.4 to HIV-1SF128A did not (Fig. 1). This
suggests that the binding of a given antibody to the same
epitope on different isolates may induce conformational
changes whose nature and extent will depend on other
structural features imposed by the viral genomic back-
ground.
What are the mechanisms for neutralization of primary
isolates? Data obtained with the anti-V3 loop MAbs
tested (Table 2) indicate that the relative degree of neu-
tralization correlates best with their relative extent of
binding to their respective epitopes following (or during),
but not prior to, virus-sCD4 association (391-95D & 257D
& 268D (Table 1)). This observation suggests that certain
functional epitopes (such as that recognized by MAb 391-
95D) within the third hypervariable region of gp120 be-
come exposed and accessible to antibody binding, and
FIG. 3. Enhancement of macrophage cell infection by (A) HIV-1SF162 are targets for neutralization, during the CD4-mediated
and (B) HIV-1SF128A mediated by MAb 654-30D. Virus (100 TCID50) was conformational changes occurring in the envelopepreincubated with serial dilutions of the anti-CD4 binding site MAb
gp120, i.e., during HIV-1-cell fusion. With regard to the654-30D and then added to primary human macrophage cells for 3 hr
at 377 as described under Materials and Methods. The inoculum was neutralization by MAb IgG1b12, it is unlikely that its high
removed and the cells were further cultivated for 7 (in the case of HIV- neutralization potential is simply due to its high affinity for
1SF162) and 10 (in the case of HIV-1SF128A) days at which point the p24 the oligomeric envelope, since its virion-binding relative
antigen concentration in the supernatant was determined. The p24
affinity was only threefold higher (0.1 mg/ml versus 0.3concentration was compared to control samples (100% infection), i.e.,
mg/ml) than that of MAb 654-30D in the HIV-1SF162 case,virus directly inoculated into macrophages without pretreatment with
MAb 654-30D. The results shown represent the mean and standard while being identical in the case of HIV-1SF128A (Table 1).
deviation of at least four independent experiments. We are currently investigating other possible mecha-
nisms by which MAb IgG1b12 might be mediating neu-
tralization of primary-like HIV-1 isolates. It is possible,
ous studies (Bernier et al., 1995), indicated that the major- for example, that virion-binding of this MAb either inhibits
ity of defective HIV-1 particles produced by two stable virion–cell binding, by blocking the binding of virions to
cell lines contained fully functional envelope proteins, cellular CD4, as stated above, or induces aberrant gp120
but lacked reverse transcriptase and/or integrase pro- structural changes, thus rendering the envelope fusion
teins. In addition, the fact that MAbs IgG1b12 and IgG- incompetent. The elucidation of the mechanism by which
CD4 (which recognize complex epitopes on gp120) bind this MAb mediates neutralization of primary HIV-1 iso-
to the same virion preparations used in the anti-V2 loop lates is crucial for the development of effective envelope-
MAb binding studies and efficiently neutralize the infec- based vaccine models.
tion of the same viruses (Table 2 and L. Stamatatos un- We consistently observe that MAbs 391-95D and
published data), suggests that the major fraction of the IgG1b12 neutralize HIV-1 infection of human primary
viral population (both infectious and noninfectious parti- macrophage cells more efficiently than infection of
cles) used in our studies has the correct (i.e., functional) PBMC. This could be due to differences in experimental
overall envelope conformation. settings for neutralization of these two cell types. How-
Although antibody-mediated gp120-virion dissociation ever, these conditions, the longer exposure of virus and
has been proposed as a possible mechanism of neutral- PBMC to MAbs than virus and macrophages, should fa-
vor a more efficient neutralization of PBMC than macro-ization of TCLA isolates (Poignard et al., 1995) our data
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FIG. 4. Exposure of gp41 epitopes occurring upon binding of anti-CD4-binding site MAbs to (A) HIV-1SF162 and (B) HIV-1SF128A virions. Sucrose-
purified virions were incubated with a constant concentration (1 mg/ml) of human anti-gp41 MAbs (50–69 or 2F5) and increasing concentrations of
anti-CD4-binding site MAbs (IgG1b12 or 654-30D). The amounts of anti-gp41 MAbs bound (OD 490 nm) to the virion surface were determined for
each concentration of anti-CD4 binding site MAb added, as described under Materials and Methods. The data represent the mean and standard
deviation of two independent experiments. The OD490 nm values shown are corrected for nonspecific MAb binding to the wells (background).
phages. Thus, we believe that the results obtained reflect of MAbs to related epitopes may induce opposite effects
on viral infectivity. The examples on hand are the anti-a true differentiation in the susceptibility of PBMC and
macrophages to neutralization. However, it is possible CD4-binding site MAbs 654-30D and IgG1b12. Both anti-
CD4 binding site MAbs 654-30D and IgG1b12 bind tothat the neutralization potential of these MAbs is influ-
enced by differences in numbers of target sites present the virion surface of the two macrophage-tropic isolates
tested with high relative affinities (based on half maximalon the two cell types. Macrophages express fewer CD4
molecules than PBMC (Collman et al., 1990) and thus, binding values) (Fig. 2 and Table 1). However, MAb
IgG1b12 mediates efficient neutralization of infectionMAb IgG1b12 might more effectively block the interaction
of virions with CD4 molecules present on the former while MAb 654-30D mediates enhancement of infection
when the target cells are primary macrophages (Table 2rather than the latter cells. In addition, the consequence
of a smaller number of CD4 molecules on the macro- and Fig. 3). It is possible that MAb 654-30D enhances
HIV-1 infectivity either via the Fc receptors present onphages could be that fewer epitopes recognized by MAb
391-95D will become exposed on virions following virion the surface of macrophage cells (Homsy et al., 1989;
Takeda et al., 1988) or in an Fc-independent fashionbinding to macrophages, and thus, MAb 391-95D would
be more effective in neutralizing infection of macro- (Schutten et al., 1995; Sullivan et al., 1995). Related to
this latter, we examined whether specific exposure ofphages than PBMC. These various possibilities require
additional investigation. gp41 epitopes occurs upon virion-MAb 654-30D binding.
Our results, however, failed to reveal any correlation be-Previous data have indicated that binding of the same
tween the extent of exposure of gp41-conformational epi-antibody to two related laboratory-adapted HIV-1 isolates
topes recognized by MAb 50-69 and 2F5 with themay result in neutralization of infection in one case, but
enhancement of infection by MAbs 654-30D or the neu-not the other (McKeating et al., 1993). Our data, however,
suggest that, in addition to considerations of extent and tralization of infection by MAb IgG1b12 (Fig. 4). Neverthe-
less, since we examined only two gp41 epitopes, theaffinity of binding and gp120-virion dissociation, binding
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